What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Read original at benzingaStocks · News reference
AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10
Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 8:31 PM
- Checked
- Aug 7, 2026, 8:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Read original at benzinga8-K filing — AbCellera Biologics Inc. (ABCL)
Filed: 2026-08-13 AccNo: 0001193125-26-349353 Size: 616 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarAbCellera Prices Oversubscribed $200.0M Offering Of 17,435,897 Common Shares At $9.75 Per Share
Read original at benzinga